OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumors
RNA-seq (gene expression) · human · 78 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 78 samples: 18 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumoursNature · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE309802_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1363200 and SRA study SRP644335. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 76 samples.
How we read this: 18 replicated groups read from 78 sample titles; they account for 76 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9282394 OR7A10
- GSM9282395 OR7A10_stop
- GSM9282396 tumor_1 tumo
- GSM9282397 tumor_2 tumo
- GSM9282398 tumor_3 tumo
- GSM9282399 tumor_4 tumo
- GSM9282400 tumor_5 tumo
- GSM9282401 tumor_6 tumo
- GSM9282402 tumor_7 tumo
- GSM9282403 tumor_8 tumo
- GSM9282404 tumor_9 tumo
- GSM9282405 tumor_10 tumo
- GSM9282406 tumor_11 tumo
- GSM9282407 tumor_12 tumo
- GSM9282408 cell_1 cell
- GSM9282409 cell_2 cell
- GSM9282410 cell_3 cell
- GSM9282411 CACAGGGT_F1 CACAGGGT_F
- GSM9282412 CACAGGGT_F2 CACAGGGT_F
- GSM9282413 CACAGGGT_F3 CACAGGGT_F
- GSM9282414 ACACTTTG_F4 ACACTTTG_F
- GSM9282415 ACACTTTG_F5 ACACTTTG_F
- GSM9282416 ACACTTTG_F6 ACACTTTG_F
- GSM9282417 ACACTTTG_F7 ACACTTTG_F
- GSM9282418 ACACTTTG_F8 ACACTTTG_F
- GSM9282419 ACACTTTG_F9 ACACTTTG_F
- GSM9282420 GTGTAAAC_F1 GTGTAAAC_F
- GSM9282421 GTGTAAAC_F2 GTGTAAAC_F
- GSM9282422 GTGTAAAC_F3 GTGTAAAC_F
- GSM9282423 GTGTAAAC_F4 GTGTAAAC_F
- GSM9282424 GTGTAAAC_F5 GTGTAAAC_F
- GSM9282425 GTGTAAAC_F6 GTGTAAAC_F
- GSM9282426 GTGTAAAC_F7 GTGTAAAC_F
- GSM9282427 GTGTAAAC_F8 GTGTAAAC_F
- GSM9282428 TGTGCCCA_F1 TGTGCCCA_F
- GSM9282429 TGTGCCCA_F2 TGTGCCCA_F
- GSM9282430 TGTGCCCA_F3 TGTGCCCA_F
- GSM9282431 TGTGCCCA_F4 TGTGCCCA_F
- GSM9282432 TGTGCCCA_F5 TGTGCCCA_F
- GSM9282433 TGTGCCCA_F6 TGTGCCCA_F
+ 38 more — browse all 78 samples with per-sample file links →
- GSE310267 OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumors 36 samples shares or7a10, car-nk, gpcr, engineering, therapy, against, boosts, solid
- GSE288846 Engineering a novel HSV-1 strain for oncolytic therapy of solid tumors 16 samples shares engineering, therapy, solid
- GSE244420 A Repressive Type of TEAD4 Condensation and Engineering a Glue Peptide Therapy Against Cancer 14 samples shares engineering, therapy, against
- GSE255046 A Repressive Type of TEAD4 Condensation and Engineering a Glue Peptide Therapy Against Cancer [RNA-Seq_TEAD4KO] 12 samples shares engineering, therapy, against
- GSE274201 A Repressive Type of TEAD4 Condensation and Engineering a Glue Peptide Therapy Against Cancer [Cut&Tag_T4] 11 samples shares engineering, therapy, against
- GSE255047 A Repressive Type of TEAD4 Condensation and Engineering a Glue Peptide Therapy Against Cancer [Cut&Tag] 6 samples shares engineering, therapy, against
- GSE255045 A Repressive Type of TEAD4 Condensation and Engineering a Glue Peptide Therapy Against Cancer [RNA-Seq399] 6 samples shares engineering, therapy, against
- GSE244418 A Repressive Type of TEAD4 Condensation and Engineering a Glue Peptide Therapy Against Cancer [ChIP-Seq 1] 6 samples shares engineering, therapy, against
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.